Friday, 15 May 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 15 May 2026
News

Pharma flags 4500 job cuts

Posted 15 May 2026 AM

Takeda has announced another round of job cuts, signalling thousands of employees will be affected globally by restructuring this year, with hopes some could transition to different roles within the Japan-headquartered company.

The cost cutting will help mitigate the loss of exclusivity of ADHD drug Vyvanse, which saw global revenue for the drug fall 43 per cent to $1.77 billion (203.2 billion yen) for the financial year. Vyvanse maintains exclusivity in Australia, although Takeda asked the government to slash the PBS list price in half.

To see the whole article, please login

Popular

What cardiologists think of Reps
'Ignored': Pharma fury at Budget fail
Pharma crowned 'Most Impactful'
Where's the action? Patients ask
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home